Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Risk Stratification
100%
Not Otherwise Specified
100%
B-cell Lymphoproliferative Disorder
100%
Risk Management
100%
Epstein-Barr Virus-positive
71%
EBV-encoded RNA
42%
Chemoimmunotherapy
28%
EBV-negative
28%
Poor Prognosis
14%
Lymphoid Neoplasms
14%
Pathological Examination
14%
Differential Diagnosis
14%
Malignant Cells
14%
Tumor Cells
14%
CD30
14%
Targeted Therapy
14%
Patient Management
14%
Clinical Trials
14%
International Prognostic Index
14%
Worse Prognosis
14%
B Symptoms
14%
Diagnostic Methods
14%
Programmed Death-ligand 1 (PD-L1)
14%
Aggressive B-cell Lymphoma
14%
Epstein-Barr Virus Infections
14%
WHO Classification
14%
Prognosis Outcome
14%
Primary Effusion Lymphoma
14%
Plasmablastic Lymphoma
14%
Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation
14%
WHO-HAEM5
14%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Epstein Barr Virus
100%
Risk Stratification
100%
Chemoimmunotherapy
18%
Diagnosis
9%
Biological Marker
9%
Diseases
9%
Neoplasm
9%
Targeted Therapy
9%
Differential Diagnosis
9%
Clinical Trial
9%
B-Cell Lymphoma
9%
Tumor Cell
9%
Chronic Inflammation
9%
Patient Care
9%
International Prognostic Index
9%
B Symptoms
9%
Epstein-Barr Virus Infection
9%
Lymphosarcoma
9%
Primary Effusion Lymphoma
9%
Plasmablastic Lymphoma
9%
Programmed Death-Ligand 1
9%